Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 100, Issue -, Pages 74-87Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2016.01.021
Keywords
Metastatic breast cancer; Anthracycline; Taxane; Capecitabine; Eribulin; Etirinotecan pegol
Categories
Funding
- Nektar Therapeutics
Ask authors/readers for more resources
Cytotoxic chemotherapy remains central to the treatment of all subtypes of metastatic breast cancer (MBC). We review evidence-based chemotherapy options for women with MBC after an anthracycline and a taxane including re-challenge with anthracycline or taxane, capecitabine, eribulin and ixabepilone as a single agent or combination with capecitabine (not approved in the EU); and the vinca alkaloid vinflunine as single agent or combined with either capecitabineigemcitabine (also not approved EU or USA). Etirinotecan pegol, comprising irinotecan bound to polyethylene glycol by a biodegradable linker, is a new cytotoxic agent for patients with MBC that has achieved encouraging response rates in phase II studies; it has been further evaluated in the phase III BEACON trial. New cytotoxics should address novel targets or modes of delivery, achieve meaningful improvements in outcomes and seek to identify predictive biomarker(s). (C) 2016 The Authors. Published by Elsevier Ireland Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available